- Ovarian cancer is the sixth most common cancer in women.
- A combination of drugs that include PARP inhibitor (Poly ADP ribose polymerase inhibitor) along with a kinase inhibitor has been found to treat ovarian cancer.
- Olaparib (PARP inhibitor) along with a P13-kinase inhibitor drug is found to show a good duration response for 5.5 months.
Ovarian cancer patients who are less likely to respond to a PARP (Poly ADP ribose polymerase) inhibitor had a partial shrinkage in the tumor when a kinase inhibitor was added for treatment, finds a new study from the Dana-Farber Cancer Institute.
Panagiotis Konstantinopoulos, MD, Ph.D., said, "When we combined the two drugs, we obtained a very good response rate - as high as 36 percent in patients with ovarian cancer that was resistant to platinum-based chemotherapy."
‘Olaparib drug along with a kinase inhibitor may help to boost treatment for ovarian cancer patients.’
The findings were presented during a clinical trials mini-symposium, at the annual meeting of the American Association for Cancer Research (AACR).
The research study was conducted with twenty-eight patients who had high-grade serous ovarian cancer. Olaparib drug is a PARP inhibitor which is given along with an investigational alpha-specific P13-Kinase inhibitor, BYL719 in phase I trial.
Out of the 26 patients, 28 of them had platinum-resistant cancer. Konstantinopoulos, medical oncologist said, that such patients responded to a PARP inhibitor for as low as 4%
Pre-clinical studies showed that adding a P13K inhibitor may sensitize the cancer cells to the effects of the PARP inhibitor and may impair the ability of tumor cells to repair the DNA damage.
The findings of the study showed that the median duration of the response in the ovarian cancer patients was about 5.5 months.
Konstantinopoulos, said, that 5.5months would be a good duration of response in the patient population. Five patients were found to be remaining on treatment at the time of presentation.
Four of the 28 patients discontinued the therapy due to toxicity.
The drug is approved for treating platinum-resistant ovarian cancer in women with germline breast cancer gene mutation. The drug mainly acts by killing the cancer cells.
- Decreased appetite
- Breathing difficulties
- Sleep disturbances
- Pale skin
In the present trial, the response rate may be 29% in women without germline BRCA (Breast cancer gene mutations). This was not much lower than the rate of 33% in patients who were without the inherited BRCA mutations.
Konstantinopoulos said, "The activity of this combination in ovarian cancer patients without germline BRCA mutations and with platinum-resistant disease was higher than expected from olaparib monotherapy and warrants further investigation."
- ( https://medlineplus.gov/druginfo/meds/a614060.html)